RE:RE:RE:RE:CR at 450
Rumpl3StiltSkin wrote: It is also the inexact nature of the delivery system for NMIBC. Once TLT gets 1433/Rutherrin into solid tumors the PR-CR %s will be a lot higher, IMO...
For deeper solid tumors, the greater challenge will not be with drug delivery, but will be with trying to achieve precise/optimal light or energy delivery in whatever form it's given. The drug has been proven to perform exceedingly well in multiple cancers preclinically, including in an NSCLC cell line as demonstrated by Roswell Park. Those TLD-1433 preclinical studies demonstrated a 100% cell kill when the proper amount of energy/fluence was administered (in this case = 20 J/cm2). So, the drug certainly works....just need to perfect the method/delivery of light or energy.